Cover Image
市場調查報告書

花生·過敏 : 開發平台分析

Peanut Allergy - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 251569
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
花生·過敏 : 開發平台分析 Peanut Allergy - Pipeline Review, H1 2017
出版日期: 2017年05月09日 內容資訊: 英文 84 Pages
簡介

花生過敏特別常見於兒童。對花生的過敏反應一般在攝取後數分鐘內發生,症狀分輕微到嚴重幾種。花生過敏的徵兆及症狀有口唇及喉嚨附近出現蕁麻疹和紅腫,發癢、刺痛,或引起像腹瀉,胃痙攣,噁心或嘔吐類的消化器官問題,喉嚨收緊,呼吸急促或發出喘息聲,或流鼻涕等。

本報告提供花生·過敏的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

花生·過敏 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • BioLingus AG
  • BioTech Tools s.a.
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • aldesleukin
  • 花生·過敏的過敏原
  • AR-101
  • ARA-LAMP-Vax
  • DBV-712
  • DN-1017
  • 花生·過敏/氣喘 CYP11A1 抑制劑
  • 呼吸系統· 免疫疾病 PIM-1 激酶抑制劑
  • PER-1080
  • pnut-ASIT
  • 花生·過敏重組蛋白品質
  • 花生·過敏 重組的載體基礎疫苗
  • VTC-064

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9246IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H1 2017, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peanut Allergy - Overview
    • Peanut Allergy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Peanut Allergy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Peanut Allergy - Companies Involved in Therapeutics Development
    • Adverum Biotechnologies Inc
    • Aimmune Therapeutics Inc
    • Alfacyte Ltd
    • Allergy Therapeutics Plc
    • AnaptysBio Inc
    • ASIT Biotech SA
    • Astellas Pharma Inc
    • BioLingus AG
    • DBV Technologies SA
    • HAL Allergy BV
    • Intrommune Therapeutics
    • Sanofi
  • Peanut Allergy - Drug Profiles
    • aldesleukin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANB-020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANN-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-0892 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DBV-712 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HALMPE-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INT-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PER-1080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pnut-ASIT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polyvac Peanut - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-439794 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine 2 for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTC-064 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peanut Allergy - Dormant Projects
  • Peanut Allergy - Discontinued Products
  • Peanut Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Mar 10, 2017: DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children
      • Mar 06, 2017: Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
      • Mar 05, 2017: Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children
      • Mar 04, 2017: AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting
      • Feb 27, 2017: Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
      • Feb 16, 2017: Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
      • Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine
      • Feb 01, 2017: Allergy Therapeutics Announces Positive Efficacy and Safety Data Shown in Peanut Allergy Vaccine
      • Dec 20, 2016: Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy
      • Dec 13, 2016: AnaptysBio Announces Clearance of U.S. IND and U.K. CTA for ANB020
      • Nov 28, 2016: Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
      • Nov 11, 2016: DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting
      • Oct 26, 2016: DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology
      • Oct 24, 2016: Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut
      • Oct 03, 2016: AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Peanut Allergy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Peanut Allergy - Pipeline by Adverum Biotechnologies Inc, H1 2017
  • Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, H1 2017
  • Peanut Allergy - Pipeline by Alfacyte Ltd, H1 2017
  • Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H1 2017
  • Peanut Allergy - Pipeline by AnaptysBio Inc, H1 2017
  • Peanut Allergy - Pipeline by ASIT Biotech SA, H1 2017
  • Peanut Allergy - Pipeline by Astellas Pharma Inc, H1 2017
  • Peanut Allergy - Pipeline by BioLingus AG, H1 2017
  • Peanut Allergy - Pipeline by DBV Technologies SA, H1 2017
  • Peanut Allergy - Pipeline by HAL Allergy BV, H1 2017
  • Peanut Allergy - Pipeline by Intrommune Therapeutics, H1 2017
  • Peanut Allergy - Pipeline by Sanofi, H1 2017
  • Peanut Allergy - Dormant Projects, H1 2017
  • Peanut Allergy - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Peanut Allergy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top